Who are Liposomal doxorubicin, Paclitaxel or Topotecan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-doxorubicin-paclitaxel-or-topotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Liposomal doxorubicin, Paclitaxel or Topotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposomal doxorubicin, Paclitaxel or Topotecan (Liposomal doxorubicin, Paclitaxel or Topotecan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (anthracycline, taxane, camptothecin analog). Area: Oncology.

phase 3 Chemotherapy combination (anthracycline, taxane, camptothecin analog) DNA (doxorubicin), β-tubulin (paclitaxel), Topoisomerase I (topotecan) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Liposomal doxorubicin, Paclitaxel or Topotecan (Liposomal doxorubicin, Paclitaxel or Topotecan) — Sichuan Baili Pharmaceutical Co., Ltd.. This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liposomal doxorubicin, Paclitaxel or Topotecan TARGET	Liposomal doxorubicin, Paclitaxel or Topotecan	Sichuan Baili Pharmaceutical Co., Ltd.	phase 3	Chemotherapy combination (anthracycline, taxane, camptothecin analog)	DNA (doxorubicin), β-tubulin (paclitaxel), Topoisomerase I (topotecan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (anthracycline, taxane, camptothecin analog) class)

Sichuan Baili Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposomal doxorubicin, Paclitaxel or Topotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-doxorubicin-paclitaxel-or-topotecan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab